THE MOST COMPLETE WEBSITE ON CLINICAL TRIALS IN HIV INFECTION (FIRST-LINE, SWITCH, PHASE 2)

Breaking News

Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection

Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection

Antiretroviral therapy for the prevention of HIV-1 transmission

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy

Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy

Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals

Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy

Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey

Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers

Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013

Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis

Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy

CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma

CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection

Human Immunodeficiency Virus Infection Does Not Worsen Prognosis of Liver Transplantation for Hepatocellular Carcinoma

Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy

Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men

Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy

Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients

Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults

Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy

Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy The D:A:D Study

Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study

TEMPRANO

START

The effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study

Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals

Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies

Influence of the Timing of Antiretroviral Therapy on the Potential for Normalization of Immune Status in Human Immunodeficiency Virus 1–Infected Individuals

Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis

Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial

Low Bone Mineral Density in Patients With Well-Suppressed HIV Infection: Association With Body Weight, Smoking, and Prior Advanced HIV Disease

Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial

A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1

Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
Published by Pedro CAHN

Updated: 15 March, 2017

Gueler A et al. AIDS. 2017 Jan 28;31(3):427-436

Objectives : To estimate life expectancy (LE) over 25 years in HIV-positive people and compare their LE with recent estimates for the general population, by education.

Methods : Patients aged 20 years or older enrolled in the Swiss HIV Cohort Study 1988-2013 were eligible. Patients alive in 2001 were matched to up to 100 Swiss residents, by sex, year of birth, and education. LE at age 20 was estimated for monotherapy (1988-1991), dual therapy (1992-1995), early combination antiretroviral therapy (cART, 1996-1998), later cART (1999-2005) and recent cART (2006-2013) eras. Parametric survival regression was used to model life expectancy.

Results : 16,532 HIV-positive patients and 927,583 residents were included. Characteristics of HIV-positive patients were : 11,916 (72.1%) were men, 11,304 (68.4%) were treatment-naïve at enrolment, and 4,707 (28.5%) had a history of current or past IDU. Median follow-up was 6.30 years (IQR 2.5-13.0 years), median age was 35 years (IQR 29-42 years), and the median CD4 cell count at enrolment was 332 cells/mm 3 (IQR 167-536). LE at age 20 of HIV-positive individuals increased from 11.8 years (95% CI 11.2-12.5) in the monotherapy era to 54.9 years (95% CI 51.2-59.6) in the most recent cART era. Differences in LE across educational levels emerged with cART. In the most recent cART period, LE at age 20 years was 52.7 years (95% CI 46.4-60.1) with compulsory education, compared to 60.0 years (53.4-67.8) with higher education. Estimates for the general population were 61.5 years and 65.6 years, respectively. In the most recent cART period, HIV-positive people continued to have an estimated LE that was lower than their peers from the general population. It was 91.5% (95% CI 84.6%-98.4%) of the matched general population for patients with higher education, 84.5% (95% CI 78.8%-90.3%) for patients with vocational training and 85.6% (95% CI 76.7%-94.6%) for patients with compulsory education. LE in highly educated patients was similar to the LE of individuals from the general population with compulsory education only. Male sex, smoking, injection drug use and low CD4 counts at enrolment were also independently associated with mortality in HIV patients.

Conclusion : In Switzerland, educational inequalities in LE were larger among HIV-infected persons than in the general population. Highly educated HIV-positive people have an estimated LE similar to Swiss residents with compulsory education. Earlier start of cART and effective smoking cessation programs could improve HIV-positive LE further and reduce inequalities.